Meeting
2020 Genitourinary Cancers Symposium
Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass (RRM) in metastatic nonseminomatous germ cell tumor (mNSGCT).
Authors
Cody Cotner
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Cody Cotner , Susan Hilton , Ronac Mamtani , Thomas J. Guzzo , David J. Vaughn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Imaging
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 391)
Abstract #
391
Poster Bd #
D12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A novel radiomics-miRNAs integrated model to predict the histopathology of residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors.
First Author: Xiangdong Li
Poster
2023 ASCO Genitourinary Cancers Symposium
Testicular radiomics correlated with pathology at time of post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumor.
First Author: Jacob Taylor
Poster
2021 ASCO Annual Meeting
Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT).
First Author: Jennifer King
Poster
2018 ASCO Annual Meeting
Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts).
First Author: Samuel Funt